- Home
- SEVN vs ACHV Comparison
SEVN vs ACHV Comparison
Compare SEVN & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ACHV
- Stock Information
- Founded
- SEVN 1986
- ACHV N/A
- Country
- SEVN United States
- ACHV United States
- Employees
- SEVN N/A
- ACHV N/A
- Industry
- SEVN Real Estate Investment Trusts
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SEVN Real Estate
- ACHV Health Care
- Exchange
- SEVN Nasdaq
- ACHV Nasdaq
- Market Cap
- SEVN 161.7M
- ACHV 131.3M
- IPO Year
- SEVN N/A
- ACHV N/A
- Fundamental
- Price
- SEVN $11.01
- ACHV $3.12
- Analyst Decision
- SEVN Strong Buy
- ACHV Strong Buy
- Analyst Count
- SEVN 2
- ACHV 2
- Target Price
- SEVN $13.50
- ACHV $16.00
- AVG Volume (30 Days)
- SEVN 46.0K
- ACHV 1.4M
- Earning Date
- SEVN 10-27-2025
- ACHV 11-06-2025
- Dividend Yield
- SEVN 10.14%
- ACHV N/A
- EPS Growth
- SEVN N/A
- ACHV N/A
- EPS
- SEVN 1.04
- ACHV N/A
- Revenue
- SEVN $29,272,000.00
- ACHV N/A
- Revenue This Year
- SEVN N/A
- ACHV N/A
- Revenue Next Year
- SEVN N/A
- ACHV N/A
- P/E Ratio
- SEVN $10.60
- ACHV N/A
- Revenue Growth
- SEVN N/A
- ACHV N/A
- 52 Week Low
- SEVN $10.01
- ACHV $1.84
- 52 Week High
- SEVN $14.66
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- SEVN 57.73
- ACHV 59.77
- Support Level
- SEVN $10.59
- ACHV $2.68
- Resistance Level
- SEVN $10.95
- ACHV $3.14
- Average True Range (ATR)
- SEVN 0.16
- ACHV 0.27
- MACD
- SEVN 0.06
- ACHV 0.01
- Stochastic Oscillator
- SEVN 89.31
- ACHV 60.64
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.